The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Analysis of ACC Late Breaking Trials

Sneak preview of our next issue of the Journal! EuroIntervention’s Deputy Editors Robert Byrne, Lars Sondergaard and Darren Mylotte along with their co-authors have prepared two editorials on the Late Breaking Trials presented during ACC 2019 which can be found below.

In their editorial and linked to the presentation of the Augustus Trial, Robert Byrne, et al. reflect on the question of the omission of aspirin after ACS or stenting in patients with oral anticoagulation. Dr. Byrne presents the dispute between experts on the role of aspirin and discusses if this is the correct way to test antithrombotic therapy and the specific question of: Why have the goalposts moved?

Partner 3 trial and Evolut Low Risk have been some of the highlights of the Congress. Deputy Editors Lars Sondergaard and Darren Mylotte have analyzed both of these trials and explain how they provide important evidence for expanding TAVI as an alternative to SAVR in patients at low surgical risk.